thumbnail image
HomeAbout UsPortfolioNewsContact Us
broken image
HomeAbout UsPortfolioNewsContact Us
中文
HomeAbout UsPortfolioNewsContact Us
HomeAbout UsPortfolioNewsContact Us
broken image
HomeAbout UsPortfolioNewsContact Us
中文
  • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

    Domain expertise, global resource, long-term capital

  • PORTFOLIO NEWS

    Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved
    2025年4月11日
    Shanghai, China, April 10, 2025 – Belief BioMed ("BBM") and Takeda China today jointly announced...
    Syneron Bio Announces Strategic Collaboration with AstraZeneca
    2025年3月21日
    BEIJING, March 21, 2025 /PRNewswire/ -- Syneron Bio, a cutting-edge oral macrocyclic peptide drug...
    Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
    2025年1月17日
    SHANGHAI, January 16th, 2025 - IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company...
    More Posts

Company

 

Shanghai

Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.

 

 

Hong Kong

Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong

 

 

US

2735 Sand Hill Road, Suite 210

Menlo Park, CA 94025

copyright © 2018 LAV all rights reserved.

沪公网安备 31010102005458号
|
沪ICP备12003647号-2
    LAV
    LAV is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
    https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More